Non-contraceptive benefits of hormonal and intrauterine reversible contraceptive methods

Human Reproduction Update

Volumn 21, Issue 5, 2015, Pages 640-651

  Bahamondes, Luis ^a   Bahamondes, M Valeria ^a   Shulman, Lee P ^b  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Copper intrauterine device; Depot medroxyprogesterone acetate; Levonorgestrel releasing intrauterine system; Non contraceptive benefits; Oral contraceptives

Indexed keywords

COMBINATION HORMONAL CONTRACEPTIVE; CONTRACEPTIVE AGENT; DROSPIRENONE PLUS ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; TAMOXIFEN; UNCLASSIFIED DRUG; LEVONORGESTREL; ORAL CONTRACEPTIVE AGENT;

ADENOMYOSIS; ANALGESIA; ANEMIA; ARTICLE; CANCER RISK; COLORECTAL CANCER; CONTRACEPTION; CONTRACEPTIVE DEVICE; COPPER INTRAUTERINE DEVICE; ECTOPIC PREGNANCY; ENDOMETRIOSIS; ENDOMETRIUM CANCER; ENDOMETRIUM HYPERPLASIA; ENDOMETRIUM POLYP; ETONOGESTREL RELEASING CONTRACEPTIVE IMPLANT; EVIDENCE BASED MEDICINE; FEMALE; HEALTH CARE CONCEPTS; HORMONAL CONTRACEPTION; HUMAN; INTRAUTERINE REVERSIBLE CONTRACEPTIVE METHOD; LEVONORGESTREL RELEASING INTRAUTERINE SYSTEM; MENORRHAGIA; NON CONTRACEPTIVE BENEFIT; ORAL CONTRACEPTION; OVARY CANCER; OVULATION INHIBITION; PAIN; PELVIC PAIN; PREMENSTRUAL DYSPHORIC DISORDER; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; RISK REDUCTION; SICKLE CELL ANEMIA; FEMALE UROGENITAL DISEASES; GENITAL NEOPLASMS, FEMALE; INTRAUTERINE CONTRACEPTIVE DEVICE; PREGNANCY; PREGNANCY, ECTOPIC; PROCEDURES;

ANEMIA; CONTRACEPTION; CONTRACEPTIVE AGENTS, FEMALE; CONTRACEPTIVES, ORAL, COMBINED; FEMALE; FEMALE UROGENITAL DISEASES; GENITAL NEOPLASMS, FEMALE; HUMANS; INTRAUTERINE DEVICES, MEDICATED; LEVONORGESTREL; PAIN; PREGNANCY; PREGNANCY, ECTOPIC; PREMENSTRUAL DYSPHORIC DISORDER;

EID: 84941961856     PISSN: 13554786     EISSN: 14602369     Source Type: Journal    
DOI: 10.1093/humupd/dmv023     Document Type: Article

References (128)

1. Abood M, Castillo Z, Guerrero F, Espino M, Austin KL. Effect of Depo-Provera or Microgynon on the painful crises of sickle cell anemia patients. Contraception 1997;56:313-316.
2. Abou-Setta AM, Al-Inany HG, Farquhar CM. Levonorgestrel-releasing intrauterine device (LNG-IUD) for symptomatic endometriosis following surgery. Cochrane Database Syst Rev 2006;4:CD005072.
3. ACOG Practice Bulletin. The use of hormonal contraception in women with coexisting medical conditions. Obstet Gynecol 2006;107:1453-1472.
4. Ahrendt HJ, Makalová D, Parke S, Mellinger U, Mansour D. Bleeding pattern and cycle control with an estradiol-based oral contraceptive: a seven-cycle, randomized comparative trial of estradiol valerate/dienogest and ethinyl estradiol/levonorgestrel. Contraception 2009;80:436-444.
5. Andersson JK, Rybo G. Levonorgestrel-releasing intrauterine device in the treatment of menorrhagia. Br J Obstet Gynaecol 1990;97:690-694.
6. Arnes M, Hvingel B, Orbo A. Levonorgestrel-impregnated intrauterine device reduces occurrence of hyperplastic polyps: a population-based follow-up cohort study. Anticancer Res 2014;34:2319-2324.
7. Bahamondes MV, Monteiro I, Castro S, Espejo-Arce X, Bahamondes L. Prospective study of the forearm bone mineral density of long-term users of the levonorgestrel-releasing intrauterine system. Hum Reprod 2010;25:1158-1164.
8. Bahamondes MV, de Lima Y, Teich V, Bahamondes L, Monteiro I. Resources and procedures in the treatment of heavy menstrual bleeding with the levonorgestrel-releasing intrauterine system (LNG-IUS) or hysterectomy in Brazil. Contraception 2012;86:244-250.
9. Bahamondes L, Bottura BF, Bahamonde MV, Gonçalves MP, Correia VM, Espejo-Arce X, Sousa MH, Monteiro I, Fernandes A. Estimated disability-adjusted life years averted by long-term provision of long acting contraceptive methods in a Brazilian clinic. Hum Reprod 2014;29:2163-2170.
10. Bayoglu Tekin Y, Dilbaz B, Altinbas SK, Dilbaz S. Postoperative medical treatment of chronic pelvic pain related to severe endometriosis: levonorgestrel-releasing intrauterine system versus gonadotropin-releasing hormone analogue. Fertil Steril 2011;95:492-496.
11. Beining RM, Dennis LK, Smith EM, Dokras A. Meta-analysis of intrauterine device use and risk of endometrial cancer. Ann Epidemiol 2008;18:492-499.
12. Benshushan A, Paltiel O, Rojansky N, Brzezinski A, Laufer N. IUD use and the risk of endometrial cancer. Eur J Obstet Gynecol Reprod Biol 2002;105:166-169.
13. Bitzer J, Amy JJ, Beerthuizen R, Birkhäuser M, Bombas T, Creinin M, Darney PD, Vicente LF, Gemzell-Danielsson K, Imthurn B et al. Statement on combined hormonal contraceptives containing third-or fourth-generation progestogens or cyproterone acetate, and the associated risk of thromboembolism. Eur J Contracept Reprod Health Care 2013;18:143-147.
14. Booth C, Inusa B, Obaro SK. Infection in sickle cell disease: a review. Int J Infect Dis 2010; 14:e2-12.
15. Bosetti C, Bravi F, Negri E, La Vecchia C. Oral contraceptives and colorectal cancer risk: a systematic review and meta-analysis. Hum Reprod Update 2009;15:489-498.
16. Bragheto AM, Caserta N, Bahamondes L, Petta CA. Effectiveness of the levonorgestrel-releasing intrauterine system in the treatment of adenomyosis diagnosed and monitored by magnetic resonance imaging. Contraception 2007;76:195-199.
17. Burkman RT, Collins JA, Shulman LP, Williams JK. Current perspectives on oral contraceptive use. Am J Obstet Gynecol 2001;185(2 Suppl):S4-12.
18. Burkman R, Schlesselman JJ, Zieman M. Safety concerns and health benefits associated with oral contraception. Am J Obstet Gynecol 2004;190:S5-22.
19. Canman CE, Chen CY, Lee MH, Kastan MB. DNA damage responses: p53 induction, cell cycle perturbations, and apoptosis. Cold Spring Harb Symp Quant Biol 1994;59:277-286.
20. Castellsagué X, Thompson WD, Dubrow R. Intra-uterine contraception and the risk of endometrial cancer. Int J Cancer 1993;54:911-916.
21. Castellsagué X, Diaz M, Vaccarella S, Sanjosé S, Muñoz N, Herrero R, Franceschi S, Meijer CJ, Bosch FX. Intrauterine device use, cervical infection with human papillomavirus, and risk of cervical cancer: a pooled analysis of 26 epidemiological studies. Lancet Oncol 2011;12:1023-1031.
22. Chan SS, Tam WH, Yeo W, Yu MM, Ng DP, Wong AW, Kwan WH, Yuen PM. A randomised controlled trial of prophylactic levonorgestrel intrauterine system in tamoxifen-treated women. BJOG 2007;114:1510-1515.
23. Chang MC. Development of the oral contraceptives. Am J Obstet Gynecol 1978;132:217-219.
24. Cheewadhanaraks S, Choksuchat C, Dhanaworavibul K, Liabsuetrakul T. Postoperative depot medroxyprogesterone acetate versus continuous oral contraceptive pills in the treatment of endometriosis-associated pain: a randomized comparative trial. Gynecol Obstet Invest 2012;74:151-156.
25. Chin J, Konje JC, Hickey M. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen. Cochrane Database Syst Rev 2009;4:CD007245.
26. Cho S, Nam A, Kim H, Chay D, Park K, Cho DJ, Park Y, Lee B. Clinical effects of the levonorgestrel releasing intrauterine device in patients with adenomyosis. Am J Obstet Gynecol 2008;198:373-377.
27. Coffee AL, Kuehl TJ, Willis S, Sulak PJ. Oral contraceptives and premenstrual symptoms: comparison of a 21/7 and extended regimen. Am J Obstet Gynecol 2006;195:1311-1319.
28. Collaborative Group on Epidemiological Studies of Ovarian Cancer, Beral V, Doll R, Hermon C, Peto R, Reeves G. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet 2008;371:303-2314.
29. Crosignani PG, Luciano A, Ray A, Bergqvist A. Subcutaneous depot medroxyprogesterone acetate versus leuprolide acetate in the treatment of endometriosis-associated pain. Hum Reprod 2006;21:248-256.
30. de Sá Rosa e Silva AC, Rosa e Silva JC, Nogueira AA, Petta CA, Abrão MS, Ferriani RA. The levonorgestrel-releasing intrauterine device reduces CA-125 serum levels in patients with endometriosis. Fertil Steril 2006;86:742-744.
31. Donnez J, Casanas-Roux F, Caprasse J, Ferin J, Thomas K. Cyclic changes in ciliation, cell height, and mitotic activity in human tubal epithelium during reproductive life. Fertil Steril 1985;43:554-559.
32. Dossus L, Allen N, Kaaks R, Bakken K, Lund E, Tjonneland A, Olsen A, Overvad K, Clavel-Chapelon F, Fournier A et al. Reproductive risk factors and endometrial cancer: the European Prospective Investigation into Cancer and Nutrition. Int J Cancer 2010;127:442-451.
33. Eissa AA, Tuck SM, Rantell K, Stott D. Trends in family planning and counselling for women with sickle cell disease in the UK over two decades. J Fam Plann Reprod Health Care 2015;41:96-101.
34. Farquhar C, Brown J. Oral contraceptive pill for heavy menstrual bleeding. Cochrane Database Syst Rev 2009;4:CD000154.
35. Fedele L, Bianchi S, Raffaelli R, Portuese A, Dorta M. Treatment of adenomyosis associated menorrhagia with a levonorgestrel-releasing intrauterine device. Fertil Steril 1997;68:426-429.
36. Fong YF, Singh K. Medical treatment of a grossly enlarged adenomyotic uterus with the levonorgestrel-releasing intrauterine system. Contraception 1999;60: 173-175.
37. Fraser IS, McCarron G. Randomized trial of 2 hormonal and 2 prostaglandin-inhibiting agents in women with a complaint of menorrhagia. Aust N Z J Obstet Gynaecol 1991;31:66-70.
38. Fraser IS, Parke S, Mellinger U, Machlitt A, Serrani M, Jensen J. Effective treatment of heavy and/or prolonged menstrual bleeding without organic cause: pooled analysis of two multinational, randomised, double-blind, placebo-controlled trials of oestradiol valerate and dienogest. Eur J Contracept Reprod Health Care 2011; 16:258-269.
39. Furlong LA. Ectopic pregnancy risk when contraception fails. A review. J Reprod Med 2002;47:881-885.
40. Gadducci A, Sergiampietri C, Tana R. Alternatives to risk-reducing surgery for ovarian cancer. Ann Oncol 2013;24(Suppl 8):viii47-viii53.
41. Gallos ID, Shehmar M, Thangaratinam S, Papapostolou TK, Coomarasamy A, Gupta JK. Oral progestogens vs levonorgestrel-releasing intrauterine system for endometrial hyperplasia: a systematic review and metaanalysis. Am J Obstet Gynecol 2010;203:547. e1-10.
42. Gallos ID, Krishan P, Shehmar M, Ganesan R, Gupta JK. LNG-IUS versus oral progestogen treatment for endometrial hyperplasia: a long-term comparative cohort study. Hum Reprod 2013a;28:2966-2971.
43. Gallos ID, Ganesan R, Gupta JK. Prediction of regression and relapse of endometrial hyperplasia with conservative therapy. Obstet Gynecol 2013b;121:1165-1171.
44. Gardner FJ, Konje JC, Abrams KR, Brown LJ, Khanna S, Al-Azzawi F, Bell SC, Taylor DJ. Endometrial protection from tamoxifen-stimulated changes by a levonorgestrel-releasing intrauterine system: a randomised controlled trial. Lancet 2000;356:1711-1717.
45. Gardner FJ, Konje JC, Bell SC, Abrams KR, Brown LJ, Taylor DJ, Habiba M. Prevention of tamoxifen induced endometrial polyps using a levonorgestrel releasing intrauterine system long-term follow-up of a randomised control trial. Gynecol Oncol 2009;114:452-456.
46. Gierisch JM, Coeytaux RR, Urrutia RP, Havrilesky LJ, Moorman PG, Lowery WJ, Dinan M, McBroom AJ, Hasselblad V, Sanders GD et al. Oral contraceptive use and risk of breast, cervical, colorectal, and endometrial cancers: a systematic review. Cancer Epidemiol Biomarkers Prev 2013;22:1931-1943.
47. Gomes MK, Ferriani RA, Rosa e Silva JC, Japur de Sá Rosa e Silva AC, Vieira CS, Cândido dos Reis FJ. The levonorgestrel-releasing intrauterine system and endometriosis staging. Fertil Steril 2007;87:1231-1234.
48. Grigorieva V, Chen-Mok M, Tarasova M, Mikhailov A. Use of a levonorgestrel-releasing intrauterine system to treat bleeding related to intrauterine leiomyomas. Fertil Steril 2003;79:1194-1198.
49. Guleria K, Agarwal N, Mishra K, Gulati R, Mehendiratta A. Evaluation of endometrial steroid receptors and cell mitotic activity in women using copper intrauterine device: can Cu-T prevent endometrial cancer? J Obstet Gynaecol Res 2004;30:181-187.
50. Gupta J, Kai J, Middleton L, Pattison H, Gray R, Daniels J; ECLIPSE Trial Collaborative Group. Levonorgestrel intrauterine system versus medical therapy for menorrhagia. N Engl J Med 2013;368:128-137.
51. Haberal A, Kayikcioglu F, Gunes M, Kaplan M, Ozdegirmenci O. The effect of the levonorgestrel intrauterine system on uterine artery blood flow 1 year after insertion. Ultrasound Obstet Gynecol 2006;27:316-319.
52. Haddad LB, Curtis KM, Legardy-Williams JK, Cwiak C, Jamieson DJ. Contraception for individuals with sickle cell disease: a systematic review of the literature. Contraception 2012;85:527-537.
53. Hale GE, Manconi F, Fraser IS. Quantitative menstrual blood loss measurement in ovulatory and anovulatory cycles in mid to late reproductive age and the menopause transition. Obstet Gynecol 2010;115:249-256.
54. Hannaford PC, Iversen L, Macfarlane TV, Elliott AM, Angus V, Lee AJ. Mortality among contraceptive pill users: cohort evidence from Royal College of General Practitioners' Oral Contraception Study. BMJ 2010;340:c927.
55. Hassell KL. Population estimates of sickle cell disease in the U.S. Am J Prev Med 2010; 38(4 Suppl):S512-S521.
56. Havrilesky LJ, Moorman PG, Lowery WJ, Coeytaux RR, Urrutia RP, Lowery WJ, Dinan M, McBroom AJ, Wing L, Sanders GD et al. Oral contraceptive pills as primary prevention for ovarian cancer: a systematic review and meta-analysis. Obstet Gynecol 2013;122:139-147.
57. Heliövaara-Peippo S, Hurskainen R, Teperi J, Aalto AM, Grénman S, Halmesmäki K, Jokela M, Kivelä A, Tomás E, Tuppurainen M et al. Quality of life and costs of levonorgestrel-releasing intrauterine system or hysterectomy in the treatment of menorrhagia: a 10-year randomized controlled trial. Am J Obstet Gynecol 2013;209:535. e1-535.e14.
58. Hill DA, Weiss NS, Voigt LF, Beresford SA. Endometrial cancer in relation to intra-uterine device use. Int J Cancer 1997;70:278-281.
59. Hoaglin DC, Filonenko A, Glickman ME, Wasiak R, Gidwani R. Use of mixed-treatment-comparison methods in estimating efficacy of treatments for heavy menstrual bleeding. Eur J Med Res 2013;18:17.
60. Horst KE, Modesitt SC. Hormonal contraceptive use for endometrial cancer prevention: physician attitudes and practices. Obstet Gynecol 2014;123(Suppl 1): 183S.
61. Hurskainen R, Teperi J, Rissanen P, Aalto AM, Grenman S, Kivelä A, Kujansuu E, Vuorma S, Yliskoski M, Paavonen J. Clinical outcomes and costs with the levonorgestrel-releasing intrauterine system or hysterectomy for treatment of menorrhagia: randomized trial 5-year follow-up. JAMA 2004;291:1456-1463.
62. Imperato F, Perniola G, Mossa B, Marziani R, Perniola F, Stragapede B, Napolitano C. The role of copper-releasing intrauterine device or levonorgestrel-releasing intrauterine system on uterine bleeding and iron status (prospective study of 8 years). Minerva Ginecol 2002;54:271-278.
63. Iodice S, Barile M, Rotmensz N, Feroce I, Bonanni B, Radice P, Bernard L, Maisonneuve P, Gandini S. Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: a meta-analysis. Eur J Cancer 2010;46:2275-2284.
64. Isaacs WA, Hayhoe FG. Steroid hormones in sickle-cell disease. Nature 1967;215:1139-1142.
65. Isaacs WA, Effiong CE, Ayeni O. Steroid treatment in the prevention of painful episodes in sickle-cell disease. Lancet 1972;1:570-571.
66. Isaacs WA, Efflong EH, Ayeni O. Steroid treatment in the prevention of painful episodes on sickle cell disease. Lancet 1975;1:570-571.
67. Jensen JT, Parke S, Mellinger U, Machlitt A, Fraser IS. Effective treatment of heavy menstrual bleeding with estradiol valerate and dienogest: a randomized controlled trial. Obstet Gynecol 2011;117:777-787.
68. Joffe H, Cohen LS, Harlow BL. Impact of oral contraceptive pill use on premenstrual mood: predictors of improvement and deterioration. Am J Obstet Gynecol 2003;189:1523-1530.
69. Johnson NP, Hummelshoj L; World Endometriosis Society Montpellier Consortium. Consensus on current management of endometriosis. Hum Reprod 2013;28:1552-1568.
70. Kadir RA, Chi C. Levonorgestrel-releasing intrauterine system: bleeding disorders and anticoagulant therapy. Contraception 2007;75:S123-S129.
71. Kaunitz AM. Progestin-releasing intrauterine systems and leiomyoma. Contraception 2007;75:S130-S133.
72. Kaunitz AM, Meredith S, Inki P, Kubba A, Sanchez-Ramos L. Levonorgestrel-releasing intrauterine system and endometrial ablation in heavy menstrual bleeding: a systematic review and meta-analysis. Obstet Gynecol 2009;113:1104-1116.
73. Kaunitz AM, Bissonnette F, Monteiro I, Lukkari-Lax E, Muysers C, Jensen JT. Levonorgestrel-releasing intrauterine system or medroxyprogesterone for heavy menstrual bleeding: a randomized controlled trial. Obstet Gynecol 2010;116:625-632.
74. Kaunitz AM, Bissonnette F, Monteiro I, Lukkari-Lax E, DeSanctis Y, Jensen J. Levonorgestrel-releasing intrauterine system for heavy menstrual bleeding improves hemoglobin and ferritin levels. Contraception 2012;86:452-457.
75. Kingman CE, Kadir RA, Lee CA, Economides DL. The use of the levonorgestrel-releasing intrauterine system for treatment of menorrhagia in women with inherited bleeding disorders. Br J Obstet Gynaecol 2004;111:1425-1428.
76. Kirton KT, Cornette JC. Return of ovulatory cyclicity following an intramuscular injection of medroxyprogesterone acetate (provera). Contraception 1974;10:39-45.
77. Lockhat FB, Emembolu JO, Konje JC. The efficacy, side-effects and continuation rates in women with symptomatic endometriosis undergoing treatment with an intra-uterine administered progestogen (levonorgestrel): a 3 year follow-up. Hum Reprod 2005;20:789-793.
78. Lu KH, Daniels M. Endometrial and ovarian cancer in women with Lynch syndrome: update in screening and prevention. Fam Cancer 2013;12:273-277.
79. Lukes AS, Reardon B, Arepally G. Use of the levonorgestrel-releasing intrauterine system in women with hemostatic disorders. Fertil Steril 2008;90:673-677.
80. Luukkainen T, Pakarinen P, Toivonen J. Progestin-releasing intrauterine systems. Semin Reprod Med 2001;19:355-363.
81. Manchikanti A, Grimes DA, Lopez LM, Schulz KF. Steroid hormones for contraception in women with sickle cell disease. Cochrane Database Syst Rev 2007;2:CD006261.
82. Marjoribanks J, Lethaby A, Farquhar C. Surgery versus medical therapy for heavy menstrual bleeding. Cochrane Database Syst Rev 2006;2:CD003855.
83. Mercorio F, DeSimone R, Di Spiezio Sardo A, Cerrota G, Bifulco G, Vanacore F, Nappi C. The effect of a levonorgestrel-releasing intrauterine system in the treatment of myoma-related menorrhagia. Contraception 2003;67:277-280.
84. Middleton LJ, Champaneria R, Daniels JP, Bhattacharya S, Cooper KG, Hilken NH, O'Donovan P, Gannon M, Gray R, Khan KS et al. Hysterectomy, endometrial destruction, and levonorgestrel releasing intrauterine system (Mirena) for heavy menstrual bleeding: systematic review and meta-analysis of data from individual patients. BMJ 2010;341:c3929.
85. Moorman PG, Havrilesky LJ, Gierisch JM, Coeytaux RR, Lowery WJ, Peragallo Urrutia R, Dinan M, McBroom AJ, Hasselblad V, Sanders GD et al. Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis. J Clin Oncol 2013;31:4188-4198.
86. Munker R, Hiller E, Paquette R. Modern Hematology: Biology and Clinical Management. Totowa, NJ: Humana Press, 2000.
87. National Heart, Lung, and Blood Advisory Council (NHLBI). www.nhlbi.nih.gov/meetings/nhlbac/. (25 July 2014, date last accessed).
88. Newcomb PA, Pocobelli G, Chia V. Why hormones protect against large bowel cancer: old ideas, new evidence. Adv Exp Med Biol 2008;617:259-269.
89. Nilsson CG, Luukkainen T, Diaz J, Allonen H. Intrauterine contraception with levonorgestrel: a comparative randomised clinical performance study. Lancet 1981;1:577-580.
90. Parazzini F, La Vecchia C, Moroni S. Intrauterine device use and risk of endometrial cancer. Br J Cancer 1994;70:672-673.
91. Parslov M, Lidegaard O, Klintorp S, Pedersen B, Jonsson L, Eriksen PS, Ottesen B. Risk factors among young women with endometrial cancer: a Danish case-control study. Am J Obstet Gynecol 2000;182:23-29.
92. Pearlstein TB, Bachmann GA, Zacur HA, Yonkers KA. Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation. Contraception 2005;72:414-421.
93. Petta CA, Ferriani RA, Abrao MS, Hassan D, Rosa E, Silva JC, Podgaec S, Bahamondes L. Randomized clinical trial of a levonorgestrel-releasing intrauterine system and a depot GnRH analogue for the treatment of chronic pelvic pain in women with endometriosis. Hum Reprod 2005;20:1993-1998.
94. Peuranpää P, Heliövaara-Peippo S, Fraser I, Paavonen J, Hurskainen R. Effects of anemia and iron deficiency on quality of life in women with heavy menstrual bleeding. Acta Obstet Gynecol Scand 2014;93:654-660.
95. Platt OS, Brambilla DJ, Rosse WF, Milner PF, Castro O, Steinberg MH, Klug PP. Mortality in sickle cell disease-Life expectancy and risk factors for early death. N Engl J Med 1994;330:1639-1644.
96. Reade CJ, McVey RM, Tone AA, Finlayson SJ, McAlpine JN, Fung-Kee-Fung M, Ferguson SE. The fallopian tube as the origin of high grade serous ovarian cancer: review of a paradigm shift. J Obstet Gynaecol Can 2014;36:133-140.
97. Rees DC, Williams TN, Gladwin MT. Sickle-cell disease. Lancet 2010;376:2018-2031.
98. Reid PC, Mukri F. Trends in number of hysterectomies performed in England for menorrhagia: examination of health episode statistics. BMJ 2005;330: 938-939.
99. Risch HA, Weiss NS, Lyon JL, Daling JR, Liff JM. Events of reproductive life and the incidence of epithelial ovarian cancer. Am J Epidemiol 1983;117:128-139.
100. Rodriguez GC, Walmer DK, Cline M, Krigman H, Lessey BA, Whitaker RS, Dodge R, Hughes CL. Effect of progestin on the ovarian epithelium of macaques: cancer prevention through apoptosis? J Soc Gynecol Investig 1998;5:271-276.
101. Rodriguez GC, Barnes HJ, Anderson KE, Whitaker RS, Berchuck A, Petitte JN, Lancaster JM, Wenham RM, Turbov JM, Day R et al. Evidence of a chemopreventive effect of progestin unrelated to ovulation on reproductive tract cancers in the egg-laying hen. Cancer Prev Res (Phila) 2013;6:1283-1292.
102. Rosenblatt KA, Thomas DB. Intrauterine devices and endometrial cancer. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Contraception 1996;54:329-332.
103. Schaedel ZE, Dolan G, Powell MC. The use of levonorgestrelreleasing intrauterine system in the management of women with hemostatic disorders. Am J Obstet Gynecol 2005;193:1361-1363.
104. Schildkraut JM, Calingaert B, Marchbanks PA, Moorman PG, Rodriguez GC. Impact of progestin and estrogen potency in oral contraceptives on ovarian cancer risk. J Natl Cancer Inst 2002;94:32-38.
105. Schlaff WD, Carson SA, Luciano A, Ross D, Bergqvist A. Subcutaneous injection of depot medroxyprogesterone acetate compared with leuprolide acetate in the treatment of endometriosis-associated pain. Fertil Steril 2006;85: 314-325.
106. Shu XO, Brinton LA, Zheng W, Gao YT, Fan J, Fraumeni JF Jr. A population-based case-control study of endometrial cancer in Shanghai, China. Int J Cancer 1991;49:38-43.
107. Shulman LP. The state of hormonal contraception today: benefits and risks of hormonal contraceptives: combined estrogen and progestin contraceptives. Am J Obstet Gynecol 2011;205(4 Suppl):S9-S13.
108. Shulman LP. The menstrual cycle (Chapter 4). In: Hatcher RA, Trussell J, Nelson AL, Cates W Jr, Kowal D, Policar MS (eds). Contraceptive Technology: Twentieth Revised Edition. Ardent Media, 2013, 69-76.
109. Shulman LP, Dungan JS. Cancer genetics: risks and mechanisms of cancer in women with inherited susceptibility to epithelial ovarian cancer. Cancer Treat Res 2010;156:69-85.
110. Soini T, Hurskainen R, Grénman S, Mäenpää J, Paavonen J, Pukkala E. Cancer risk in women using the levonorgestrel-releasing intrauterine system in Finland. Obstet Gynecol 2014;124:292-299.
111. Soliman PT, Oh JC, Schmeler KM, Sun CC, Slomovitz BM, Gershenson DM, Burke TW, Lu KH. Risk factors for young premenopausal women with endometrial cancer. Obstet Gynecol 2005;105:575-580.
112. Soysal S, Soysal ME. The efficacy of levonorgestrel-releasing intrauterine device in selected cases of myoma-related menorrhagia. Gynecol Obstet Invest 2005;5:29-35.
113. Sturgeon SR, Brinton LA, Berman ML, Mortel R, Twiggs LB, Barrett RJ, Wilbanks GD, Lurain JR. Intrauterine device use and endometrial cancer risk. Int J Epidemiol 1997;26:496-500.
114. Szarewski A, Mansour D, Shulman LP. 50 years of 'The Pill': celebrating a golden anniversary. J Fam Plann Reprod Health Care 2010;36:231-238.
115. Tanmahasamut P, Rattanachaiyanont M, Angsuwathana S, Techatraisak K, Indhavivadhana S, Leerasiri P. Postoperative levonorgestrel-releasing intrauterine system for pelvic endometriosis-related pain: a randomized controlled trial. Obstet Gynecol 2012;119:519-526.
116. Varma R, Soneja H, Bhatia K, Ganesan R, Rollason T, Clark TJ, Gupta JK. The effectiveness of a levonorgestrel-releasing intrauterine system (LNG-IUS) in the treatment of endometrial hyperplasia-a long-term follow-up study. Eur J Obstet Gynecol Reprod Biol 2008;139:169-175.
117. Vercellini P, De Giorgi O, Oldani S, Cortesi I, Panazza S, Crosignani PG. Depot medroxyprogesterone acetate versus an oral contraceptive combined with very-low dose danazol for long-term treatment of pelvic pain associated with endometriosis. Am J Obstet Gynecol 1996;175:396-401.
118. Vercellini P, Frontino G, De Giorgi O, Aimi G, Zaina B, Crosignani PG. Comparison of a levonorgestrel-releasing intrauterine device versus expectant management after conservative surgery for symptomatic endometriosis: a pilot study. Fertil Steril 2003;80:305-309.
119. Vilos GA, Tureanu V, Garcia M, Basim AR. The levonorgestrel intrauterine system is an effective treatment in women with abnormal uterine bleeding and anticoagulant therapy. J Min Invas Gynecol 2009;16:480-484.
120. Walch K, Unfried G, Huber J, Kurz C, van Trotsenburg M, Pernicka E, Wenzl R. Implanonw versus medroxyprogesterone acetate: effects on pain scores in patients with symptomatic endometriosis-a pilot study. Contraception 2009;79:29-34.
121. Weiss NS, Sayvetz TA. Incidence of endometrial cancer in relation to the use of oral contraceptives. N Engl J Med 1980;302:551-554.
122. Wilailak S, Vipupinyo C, Suraseranivong V, Chotivanich K, Kietpeerakool C, Tanapat Y, Therasakvichya S, Hamontri S, Linasmita V, Bunyapipat S et al. Depot medroxyprogesterone acetate and epithelial ovarian cancer: a multicentre case-control study. BJOG 2012;119:672-677.
123. Winner B, Peipert JF, Zhao Q, Buckel C, Madden T, Allsworth JE, Secura GM. Effectiveness of long-acting reversible contraception. N Engl J Med 2012;366:1998-2007.
124. Wong AW, Chan SS, Yeo W, Yu MY, Tam WH. Prophylactic use of levonorgestrel-releasing intrauterine system in women with breast cancer treated with tamoxifen: a randomized controlled trial. Obstet Gynecol 2013;121:943-950.
125. Xiao B, Wu SC, Chong J, Zeng T, Han LH, Luukkainen T. Therapeutic effects of the levonorgestrel-releasing intrauterine system in the treatment of idiopathic menorrhagia. Fertil Steril 2003;79:963-969.
126. Xu L, Lee BS, Asif S, Kraemer P, Inki P. Satisfaction and health-related quality of life in women with heavy menstrual bleeding; results from a non-interventional trial of the levonorgestrel-releasing intrauterine system or conventional medical therapy. Int J Womens Health 2014;6:547-554.
127. Yonkers KA, Brown C, Pearlstein TB, Foegh M, Sampson-Landers C, Rapkin A. Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstet Gynecol 2005;106:492-501.
128. Zorbas KA, Economopoulos KP, Vlahos NF. Continuous versus cyclic oral contraceptives for the treatment of endometriosis: a systematic review. Arch Gynecol Obstet 2015;292:37-43.